f Post-Approval Studies (PAS) Database
Quick Links: Skip to main page content Skip to Search Skip to Topics Menu Skip to Common Links
  • Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Post-Approval Studies (PAS) Database
  • Print
  • Share
  • E-mail
-

The FDA has the authority to require sponsors to perform a post-approval study (or studies) at the time of approval of a premarket approval (PMA), humanitarian device exemption (HDE), or product development protocol (PDP) application. Post-approval studies can provide patients, health care professionals, the device industry, the FDA and other stakeholders information on the continued safety and effectiveness (or continued probable benefit, in the case of an HDE) of approved medical devices. This database allows you to search Post-Approval Study information by applicant or device information.

Learn more...


           

Alterra New Enrollment Study


Suggest Enhancement / Report Issue | export reports to excelExport to Excel
General
Study Status Ongoing
Application Number /
Requirement Number		 P200015 S011/ PAS002
Date Original Protocol Accepted 12/16/2021
Date Current Protocol Accepted 03/03/2023
Study Name Alterra New Enrollment Study
Device Name Edwards SAPIEN 3 Transcatheter Pulmonary Valve System with Alterra Adaptive Prestent
General Study Protocol Parameters
Study Design Prospective Cohort Study
Data Source New Data Collection
Comparison Group Historical Control
Analysis Type Descriptive
Study Population Child: 2-12 yrs, Adolescent: 13-18 yrs, Transit. Adolescent A (distinctively) : 18-21 yrs, Adult: >21
Detailed Study Protocol Parameters
Study Objectives This is a prospective, multi-center, single-arm new enrollment study. The objective of the study is to characterize the real-world performance of the Edwards SAPIEN 3 Transcatheter Pulmonary Valve System with Edwards Alterra Adaptive Prestent through 10 years post implant.
Study Population Patients with severe pulmonary regurgitation who have a native or surgically-repaired right ventricular outflow tract and are clinically indicated for pulmonary valve replacement.
Sample Size 150
Key Study Endpoints Acute device success, transcatheter heart valve dysfunction, echocardiographic assessments, New York Heart Association (NYHA) functional class, and adverse events device (including device frame fracture).
Follow-up Visits and Length of Follow-up 10 years


Alterra New Enrollment Study Reporting Schedule

Reporting Schedule
Report
Date Due
FDA Receipt
Date
Applicant's Reporting Status
1 year report 12/16/2022 12/15/2022 On Time
2 year report 01/29/2024 01/29/2024 On Time
3 year report 01/29/2025    
4 year report 01/29/2026    
5 year report 01/29/2027    
6 year report 01/29/2028    
7 year report 01/29/2029    
8 year report 01/29/2030    
9 year report 01/29/2031    
10 year report 01/29/2032    
11 year report 01/29/2033    
12 year report 01/29/2034    


Contact Us
Mandated Studies Program
Food and Drug Administration
10903 New Hampshire Ave.
Silver Spring, MD 20993-0002
Email: MandatedStudiesPrograms@fda.hhs.gov

Additional Resources

-
-